Skip to content
SPACListing
CompletedNasdaq

NewGenIvf Group LtdNIVF

Class A NIVFWarrants NIVFWCIK 0001981662

Cash in trust

—

Not yet disclosed

Trust per share

—

Not yet disclosed

IPO

Sep 2026

—

Combination deadline

—

Not disclosed

Filings on record

197

Latest Nov 13, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
Jul 14, 2023
Closed
Mar 1, 2024

Overview

NewGenIvf Group Ltd is a special purpose acquisition company incorporated in Virgin Islands, British and registered with the SEC under CIK 0001981662. It completed its initial public offering in Sep 2026 and listing on Nasdaq. Class A shares trade under the ticker NIVF, warrants under NIVFW on Nasdaq. The vehicle is sponsored by NewGenIvf. Business combination closed; the company trades under a new ticker.

How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

13702023-062026-11

197 filings in all. 24 in the last three months, against a busiest month of 13.

News on NewGenIvf Group Ltd

Last 90 days

News sentiment

Positive
negativeneutralpositive

Across 1 recent story, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.

SEC filing history

Free tier: filings older than 24 hours
  • EFFECT

    Notice of effectiveness

    Accession 9999999995-26-003533

    Nov 13, 2026

    1d ago

    View on EDGAR ↗
  • F-3/A

    AMENDMENT NO. 1 TO FORM F-3

    Accession 0001213900-26-117158

    Nov 9, 2026

    5d ago

    View on EDGAR ↗
  • F-3

    REGISTRATION STATEMENT

    Accession 0001213900-26-112724

    Oct 27, 2026

    18d ago

    View on EDGAR ↗
  • 6-K/A

    AMENDMENT NO. 1 TO FORM 6-K

    Accession 0001213900-26-112647

    Oct 27, 2026

    18d ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-111191

    Oct 21, 2026

    24d ago

    View on EDGAR ↗
  • DRS

    Draft registration statement (confidential)

    Accession 0001213900-26-108200

    Oct 9, 2026

    1mo ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-107570

    Oct 7, 2026

    1mo ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-107372

    Oct 7, 2026

    1mo ago

    View on EDGAR ↗
  • SCHEDULE 13D/A

    SCHEDULE 13D/A filing

    Accession 0001213900-26-107054

    Oct 6, 2026

    1mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001213900-26-107053

    Oct 6, 2026

    1mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001213900-26-107052

    Oct 6, 2026

    1mo ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-106620

    Oct 5, 2026

    1mo ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-105211

    Sep 30, 2026

    1mo ago

    View on EDGAR ↗
  • 424B4

    Final IPO prospectus

    Accession 0001213900-26-104917

    Sep 30, 2026

    1mo ago

    View on EDGAR ↗
  • EFFECT

    Notice of effectiveness

    Accession 9999999995-26-003079

    Sep 29, 2026

    1mo ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001213900-26-102982

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001213900-26-102945

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • F-1/A

    AMENDMENT NO. 2 TO FORM F-1

    Accession 0001213900-26-098823

    Sep 10, 2026

    2mo ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001213900-26-097416

    Sep 4, 2026

    2mo ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001213900-26-096451

    Sep 2, 2026

    2mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001213900-26-096450

    Sep 2, 2026

    2mo ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001213900-26-096449

    Sep 2, 2026

    2mo ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001213900-26-096250

    Sep 1, 2026

    2mo ago

    View on EDGAR ↗
  • F-1/A

    AMENDMENT NO. 1 TO FORM F-1

    Accession 0001213900-26-096245

    Sep 1, 2026

    2mo ago

    View on EDGAR ↗
  • UPLOAD

    SEC staff comment letter

    Accession 0000000000-26-008475

    Aug 27, 2026

    2mo ago

    View on EDGAR ↗
  • F-1

    REGISTRATION STATEMENT

    Accession 0001213900-26-091922

    Aug 20, 2026

    2mo ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001213900-26-091925

    Aug 20, 2026

    2mo ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001213900-26-091873

    Aug 20, 2026

    2mo ago

    View on EDGAR ↗
  • 6-K

    REPORT OF FOREIGN PRIVATE ISSUER

    Accession 0001213900-26-091212

    Aug 18, 2026

    2mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001213900-26-091211

    Aug 18, 2026

    2mo ago

    View on EDGAR ↗

Pro

Track NIVF without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

NewGenIvf Group Ltd: questions answered

What is NewGenIvf Group Ltd (NIVF)?

NewGenIvf Group Ltd is a special purpose acquisition company incorporated in Virgin Islands, British and registered with the SEC under CIK 0001981662. It completed its initial public offering in Sep 2026 and listing on Nasdaq. Class A shares trade under the ticker NIVF, warrants under NIVFW on Nasdaq. The vehicle is sponsored by NewGenIvf. Business combination closed; the company trades under a new ticker.

How much does NewGenIvf Group Ltd hold in trust?

No trust balance has been disclosed in a filing we have indexed for NewGenIvf Group Ltd. For a newly priced IPO this is normal: the figure first appears in the quarterly report after closing.

When must NewGenIvf Group Ltd complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if NewGenIvf Group Ltd does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in NewGenIvf Group Ltd, and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does NewGenIvf Group Ltd trade under?

Class A shares trade as NIVF on Nasdaq, and the warrants as NIVFW. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for NewGenIvf Group Ltd?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

Who sponsors NewGenIvf Group Ltd, and what is their track record?

NewGenIvf is the sponsor entity, part of the NewGenIvf franchise. This is the only vehicle we have attributed to that sponsor.

Is NewGenIvf Group Ltd tradeable, and where?

Yes. NIVF returned a live quote of $0.23 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is NewGenIvf Group Ltd a good investment?

That is not a question this site answers. NewGenIvf Group Ltd is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this NewGenIvf Group Ltd data come from?

Filings NewGenIvf Group Ltd submitted to the SEC under CIK 0001981662: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Nov 14, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.